This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Prosensa To Present At The 66th Annual American Academy Of Neurology (AAN) Annual Meeting And The 39th Annual Deutsche Bank Health Care Conference

Stocks in this article: RNA

Leiden, The Netherlands, April 28, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that it will present at the following US conferences:

66 th American Academy of Neurology (AAN) Annual Meeting,  Philadelphia, PA

Poster presentation: Emerging Science Session: 6:15pm EDT on Wednesday, April 30, 2014

Drisapersen treatment for Duchenne muscular dystrophy: results of a 96-week follow-up of an open-label extension study following two placebo-controlled trials

Presenter: Dr. Nathalie Goemans

The poster includes results up to Week 48 from the second open-label extension study of drisapersen treatment in boys with DMD (DEMAND IV/DMD114349), who had previously completed a 48-week, double-blind, placebo-controlled treatment phase in one of two Phase II feeder studies (DEMAND II/DMD114117 and DEMAND III/DMD114044).

Breakfast Briefing (by invitation only) : 7:30 -9:00am EDT on Thursday, May 1, 2014

Corporate Update: Hans Schikan, CEO & Giles Campion, CMO

Poster Presentation: Dr. Nathalie Goemans

Q&A: Prosensa Management, Dr. Nathalie Goemans (live) and Dr. Craig McDonald (by phone)

Dr. Goemans is a pediatrician, child neurologist and Head of the Neuromuscular Reference Center for Children at the University Hospitals Leuven (UHL). She is actively involved in the development of protocols for international multicentre trials and is an investigator in clinical trials in Duchenne Muscular Dystrophy (DMD).

Dr. McDonald is a Professor and Chair of Physical Medicine and Rehabilitation and a Professor of Pediatrics at the University of California Davis School of Medicine. He is an internationally recognized expert in the clinical management and rehabilitation of neuromuscular diseases including muscular dystrophies and the development of novel outcome measures for clinical trials. 

39 th Annual Deutsche Bank Health Care Conference, Boston, MA

Fireside Chat: 2:10pm EDT on Wednesday, May 7, 2014; Berndt Modig, CFO

Live webcasts of Prosensa's presentations at the AAN Breakfast Briefing and the Deutsche Bank Health Care Conference will be accessible through the Investors & Media section of the corporate website at http://ir.prosensa.eu/events.cfm and will be archived for 90 days. 

Notes to editors

About Prosensa Holding N.V.

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington's disease.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,410.23 +218.86 1.27%
S&P 500 2,015.68 +13.52 0.68%
NASDAQ 4,668.4640 +30.47 0.66%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs